http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 18 May 2026 05:08:43 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Quantum+BioPharma+reaches+halfway+point+in+imaging+study+with+MGH/26509360.html <p>Quantum BioPharma Ltd. (NASDAQ: QNTM) announced that patient enrollment has reached the midpoint in its collaborative imaging study with Massachusetts General Hospital. The study aims to validate a positron emission tomography imaging technique for assessing demyelinated neurons in multiple sclerosis patients.</p><p>The research centers on the PET tracer [¹⁸F]3F4AP, developed by Pedro Brugarolas from MGH's Department of Radiology and Harvard Medical School. Early data from the first cohort shows signal detection in acute MS lesions and potential sensitivity to gray matter lesions using PET/MR and total-body PET platforms.</p><p>The imaging technique is designed to directly measure demyelinated lesions with intact axons and http://www.streetinsider.com/Corporate+News/Quantum+BioPharma+reaches+halfway+point+in+imaging+study+with+MGH/26509360.html Mon, 18 May 2026 05:08:43 -0400 0K91 QNTM http://www.streetinsider.com/Corporate+News/Quantum+BioPharma+reaches+halfway+point+in+imaging+study+with+MGH/26509360.html <p>Quantum BioPharma Ltd. (NASDAQ: QNTM) announced that patient enrollment has reached the midpoint in its collaborative imaging study with Massachusetts General Hospital. The study aims to validate a positron emission tomography imaging technique for assessing demyelinated neurons in multiple sclerosis patients.</p><p>The research centers on the PET tracer [¹⁸F]3F4AP, developed by Pedro Brugarolas from MGH's Department of Radiology and Harvard Medical School. Early data from the first cohort shows signal detection in acute MS lesions and potential sensitivity to gray matter lesions using PET/MR and total-body PET platforms.</p><p>The imaging technique is designed to directly measure demyelinated lesions with intact axons and http://www.streetinsider.com/Corporate+News/Quantum+BioPharma+reaches+halfway+point+in+imaging+study+with+MGH/26509360.html Mon, 18 May 2026 05:08:43 -0400 0K91 QNTM http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html <p align="left">TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Reaches+Key+Midpoint+Milestone+in+Groundbreaking+Imaging+Study+with+Massachusetts+General+Hospital/26509179.html Mon, 18 May 2026 03:00:00 -0400 0K91 A.06822034 A.35954321 A.40221050 O.20026344 O.20042365 O.20737027 O.39443675 QNTM QNTM http://www.streetinsider.com/Press+Releases/Quantum+Reports+Strengthened+Liquidity%2C+Reduced+Cash+Burn%2C+and+Disciplined+Cost+Management+in+First+Quarter+2026/26447888.html <p align="justify">TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), has reported its financial and operational results for the first quarter of 2026, ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Financial Results</strong></p> <p align="justify">As of March 31, 2026, the Company’s combined cash and cash equivalents, and digital assets, totaled US$9.8 million, more than doubled from US$4.1 million as of December 31, 2025. Management confirms that current liquidity is sufficient to fund planned operations to approximately July 2027.</p> <p align="justify">As of the date of http://www.streetinsider.com/Press+Releases/Quantum+Reports+Strengthened+Liquidity%2C+Reduced+Cash+Burn%2C+and+Disciplined+Cost+Management+in+First+Quarter+2026/26447888.html Thu, 07 May 2026 07:00:00 -0400 0K91 A.38008731 A.50216349 O.34919279 O.39443675 O.45219770 QNTM QNTM http://www.streetinsider.com/Press+Releases/Quantum+Reports+Strengthened+Liquidity%2C+Reduced+Cash+Burn%2C+and+Disciplined+Cost+Management+in+First+Quarter+2026/26447888.html <p align="justify">TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), has reported its financial and operational results for the first quarter of 2026, ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Financial Results</strong></p> <p align="justify">As of March 31, 2026, the Company’s combined cash and cash equivalents, and digital assets, totaled US$9.8 million, more than doubled from US$4.1 million as of December 31, 2025. Management confirms that current liquidity is sufficient to fund planned operations to approximately July 2027.</p> <p align="justify">As of the date of http://www.streetinsider.com/Press+Releases/Quantum+Reports+Strengthened+Liquidity%2C+Reduced+Cash+Burn%2C+and+Disciplined+Cost+Management+in+First+Quarter+2026/26447888.html Thu, 07 May 2026 07:00:00 -0400 0K91 A.38008731 A.50216349 O.34919279 O.39443675 O.45219770 QNTM QNTM http://www.streetinsider.com/Press+Releases/Quantum+Reports+Strengthened+Liquidity%2C+Reduced+Cash+Burn%2C+and+Disciplined+Cost+Management+in+First+Quarter+2026/26447888.html <p align="justify">TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</strong>” or the “<strong>Company</strong>”), has reported its financial and operational results for the first quarter of 2026, ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Financial Results</strong></p> <p align="justify">As of March 31, 2026, the Company’s combined cash and cash equivalents, and digital assets, totaled US$9.8 million, more than doubled from US$4.1 million as of December 31, 2025. Management confirms that current liquidity is sufficient to fund planned operations to approximately July 2027.</p> <p align="justify">As of the date of http://www.streetinsider.com/Press+Releases/Quantum+Reports+Strengthened+Liquidity%2C+Reduced+Cash+Burn%2C+and+Disciplined+Cost+Management+in+First+Quarter+2026/26447888.html Thu, 07 May 2026 07:00:00 -0400 0K91 A.38008731 A.50216349 O.34919279 O.39443675 O.45219770 QNTM QNTM